May 1, 2012 (New Orleans, Louisiana) — A transdermal patch that delivers 8 mg of the dopamine-receptor agonist rotigotine (Neupro, UCB) in a once-daily, single application is the lowest effective dose ...
August 4, 2011 — A new study is the first long-term prospective trial of dopamine agonist therapy in restless legs syndrome (RLS). The study, funded by UCB BioSciences and Schwarz Pharma, ...
BioNxt Solutions (OTCQB:BNXTF) has executed an agreement to carry out comparative drug absorption study for its transdermal (TDS) Rotigotine patch for the treatment of Parkinson's disease. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback